The U.S. Food and Drug Administration has delayed reviews of two drugs chosen for the Trump administration's new fast-track ...

A plan to slash Food and Drug Administration drug review times is raising alarms at the public health agency that's been ...

Questions remain among top Food and Drug Administration officials over who has the appropriate legal authority to sign off on ...

FDA delays drug reviews for two priority voucher drugs amid safety and efficacy concerns, extending timelines for Sanofi and Disc Medicine products.

Dr. Martin Makary testifies during his confirmation hearing before the Senate Committee on Health, Education, Labor, and Pensions Committee on March 06, 2025, in Washington, DC. This story was ...

Food and Drug Administration commissioner Marty Makary's flagship effort to overhaul how the agency reviews drugs is facing intensifying scrutiny from Congress and the medical establishment over ...

The U.S. Food and Drug Administration has delayed reviews of several drugs selected for the Trump administrations new ...

Southwest General Health Center will host sessions on January 8 and February 12 where pharmacists will examine prescription ...

Health system pharmacists and clinicians are monitoring a wave of drug approvals expected throughout 2026, including first-in-class therapies and expanded uses of existing drugs with implications for ...

Geriatrics and Aging. 2005;8(6):43-45. Is the treatment still indicated or has the diagnosis been refuted? For example, a putative diagnosis of angina may have subsequently been disproved. Treatments ...